Opiates and their immunomodulation properties;Opiáty a jejich imunomodulační vlastnosti

Casopis Lekaru Ceskych

Volumn 142, Issue 4, 2003, Pages 244-247

  Blahoutova V ^a   Zajicova A ^a   Wilczek, H ^b   Holáň, Vladimír ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Heroin; Immune system; Methadone; Morphine; Opiates; Substitution treatment

Indexed keywords

DIAMORPHINE; ILLICIT DRUG; METHADONE; MORPHINE; OPIATE DERIVATIVE; OPIATE RECEPTOR;

BACTERIAL INFECTION; CANCER PAIN; CELL FUNCTION; CELL PROLIFERATION; CELL SURFACE; DRUG ABUSE; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; EUPHORIA; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOLOGICAL PARAMETERS; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; MACROPHAGE; NERVOUS SYSTEM; NEUROPATHIC PAIN; NONHUMAN; REVIEW; TIME; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; IMMUNE SYSTEM; NARCOTICS;

EID: 0037660492     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Dole, V. P., Nyswander, M. E.: Heroin addiction - a metabolic disease. Arch. Intern. Med., 123, 1967, s. 1441-1442.
2. Ableitner, A., Schultz, R.: Neuroanatomical sites mediating the central actions of β-endorphin as mapped by changes in glucose utilization: Involvement of mu opioid receptors. J. Pharmacol. Exp. Ther., 262, 1992, s. 415-423.
3. Bryant, H. U., Bernton, E. W., Holaday, J. W.: Immunosuppressive effects of chronic morphine treatment in mice. Life Sci., 41, 1987, s. 1731-1738.
4. Stefano, G. B., Goumon,A., Casares, F. et al.: Endogenous morphine. TIPS, 23, 2000, s. 436-442.
5. Pacifici, R., di Carlo, S., Bacosi, A., Pichini, S.: Pharmacokinetics and cytokine production in heroin and morphine-treated mice. Int. J. Pharmacol., 22, 2000, s. 603-614.
6. Smith, M. T., Watt, J. A., Cramond, T.: Morphine-3-glucuronide-a potent antagonist of morphine analgesia. Life Sci., 47, 1990, s. 579-585.
7. Kolesnikov, Y. A., Jain, S., Wilson, R., Pasternak, G. W.: Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance. J. Pharmacol. Exp. Ther., 179, 1996, s. 502-506.
8. Pasternak, G. W., Bodnar, R. J., Clark, J. A., Inturrisi, C. E.: Morphine-6-glucuronide, a potent mu agonist. Life Sci., 41, 1987, s. 2845-2849.
9. Carr, D. J., Bost, K. L., Blalock, J. E.: The production of antibodies which recognize opiate receptors on murine leukocytes. Life Sci., 42, 1988, s. 2615-2624.
10. Owen, J. A., Nakatsu, K.: Diacetylmorphine (heroin) hydrolases in human blood. Can. J. Physiol. Pharmacol., 61, 1983, s. 870-875.
11. Kamendulis, L. M., Brzezinski, M. R., Pindel, E. V. et al.: Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J. Pharmacol. Exp. Ther., 279, 1996, s. 713-717.
12. Selley, D. E., Cheng-Chun, C., Sexton, et al.: Mu-opioid receptor-mediated G-protein activation by heroin metabolites: evidence for the efficacy of 6-monoacetylmorphine compared with morphine. Biochem. Pharmacol., 62, 2001, s. 447-455.
13. Kreek, M. J., Hachey, D. L., Klein, P. D.: Stereoselective disposition of methadone in man. Life Sci., 24, 1979, s. 925-932.
14. Liu, S. J., Roerig, D. L., Wang, R. I.: Brain and plasma levels of methadone and their relationship to analgesic activity of methadon in rats. Drug Metab. Dispos., 11, 1983, s. 335-338.
15. Wilczek, H.: Lze léčit narkomany? Trendy v medicíně, 3, 2000, s. 48-55.
16. Vavřinková, B., Binder, T., Podrapská, J., Popov, P.: Prvnf těhotenství a porod v rámci metadonového programu v ČR. Čes. Gynek., 65, 2000, s. 273-274.
17. Wilczek, H., Holakovský, J., Kovářová, Š., Mazánek, J.: Stomatologická ošetření v celková anestezii u pacientů v metadonovém programu. Čes. Stomat., 2, 1999, s. 45-48.
18. Novick, D. M., Ochshorn, M., Ghali, V. et al.: Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J. Pharmacol. Exp. Ther., 250, 1989, s. 606-610.
19. Tubaro, E., Santiangeli, C., Belogi, L. et al.: Methadone vs. morphine: comparison of their effect on phagocytic functions. Int. J. Immun., 9, 1987, s. 79-88.
20. Bayer, B. M., Gastonguay, M. R., Hernandez, M. C.: Distinction between the in vitro and in vivo inhibitory effects of morphine on lymphocyte proliferation based on agonist sensitivity and naltrexone reversibility. Immunopharmacology, 23, 1992, s. 117-124.
21. Fecho, K., Maslonek, K. A., Dykstra, L. A., Lysle, D. T.: Assessment of the involvement of central nervous system and peripheral opioid receptors in the immunomodulatory effects of acute morphine treatment in rats. J. Pharmacol. Exp. Ther., 276, 1996, s. 626-636.
22. Bryant, H. U., Roudebush, R. E.: Suppressive effects of morphine pellet implants on in vivo parameters of immune function. J. Pharmacol. Exp. Ther., 255, 1990, s. 410-414.
23. Roy, S., Wang, J. H., Balasubramanian, S. et al.: Morphine directs T cells toward Th2 differentiation. Surgery, 130, 2001, s. 304-309.
24. Pacifici, R., Minneti, M., Zuccaro, P., Pietraforte, D.: Morphine affects cytostatic activity of macrophages by the modulation of nitric oxide release. Int. J. Pharmacol., 17, 1995, s. 771-777.
25. Fecho, K., Maslonek, K. A., Dykstra, L. A., Lysle, D. T.: Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats. J. Pharmacol. Exp. Ther., 277, 1996, s. 633-645.
26. Flores, L. R., Wahl, S. M., Bayer, B. M.: Mechanisms of morphine-induced immunosuppression: effect of acute morphine administration on lymphocyte trafficking. J. Pharmacol. Exp. Ther., 272, 1995, s. 1246 až 1251.
27. Scott, M., Carr, D. J.: Morphine suppresses the alloantigen-driven CTL response in a dose-dependent and naltrexone reversible manner. J. Pharmacol. Exp. Ther., 278, 1996, s. 980-988.
28. Nair, M. P. N., Schwartz, S. A., Polasani, R. et al.: Immunoregulatory effects of morphine on human lymphocytes. Clin. Diagn. Lab. Immunol., 4, 1997, s. 127-132.
29. Peng, X., Mosser, D. M., Adler, M. W. et al.: Morphine inhances interleukin-12 and the production of other pro-inflammatory cytokines in mouse peritoneal macrophages. J. Leuk. Biol., 68, 2000, s. 723-728.
30. Holáň, V., Zajícová, A., Krulová, M. et al.: Augmented production of proinflammatory cytokines and accelerated allotransplantation reactions in heroin-treated mice. Clin. Exp. Immunol. (v tisku).
31. Ishikawa, M., Tanno, K., Kamo, A. et al.: Enhancement of tumour growth by morphine and its possible mechanism in mice. Biol. Pharm. Bull., 16, 1993, s. 762-766.
32. Bohn, L. M., Belcheva, M. M., Coscia, C. J.: Mu-opioid agonist inhibition of kappa-opioid receptor-stimulated extracellular signal-regulated kinase phosphorylation is dynamin-dependent in C6 glioma cells. J. Neurochem., 74, 2000, s. 274-281.
33. Hatzoglou, A., Bakogeorgou, E., Castanas, E.: The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. Eur. J. Pharmacol., 296, 1996, s. 199-207.
34. Zagon, I. S., McLaughlin, P. J.: Heroin prolongs survival time and retards tumor growth in mice with neuroblastoma. Brain Res. Bull., 7, 1981, s. 25-32.
35. MacFarlane, A. S., Peng, X., Meissler, J. J. Jr. et al.: Morphine increases susceptibility to oral Salmonella typhimurium infection. J. Infect. Dis., 181, 2000, s. 1350-1358.
36. Nelson, C. J., How, T., Lysle, D. T.: Enhancement of the contact hypersensitivity reaction by acute morphine administration at the elicitation phase. Clin. Immunol., 93, 1999, s. 176-183.
37. Zubelewicz, B., Muc-Wierzgon, M., Harbuz, M. S., Brodziak, A.: Central single and chronic administration of morphine stimulates corticosterone and interleukin (IL)-6 in adjuvant-induced arthritis. J. Physiol. Pharmacol., 51, 2000, s. 897-906.
38. Houghtling, R. A., Mellon, R. D., Tan, R. J., Bayer, B. M.: Acute effects of morphine on blood lymphocyte proliferation and plasma IL-6 levels. Ann. N.Y. Acad. Sci., 917, 2000, s. 771-777.